Blog
RSS FeedPosted by Michael Wonder on 17 Mar 2021
Mythbusting PHARMAC
17 March 2021 - The agency is seeking to dispel some misunderstandings about what it does and how it does ...
Posted by Michael Wonder on 17 Mar 2021
PHARMAC’s drug switch
17 March 2021 - PHARMAC's generic drug swap for epilepsy treatment saved $30 million over five years. But for some ...
Posted by Michael Wonder on 08 Mar 2021
Pacific pharmacists want inclusion on PHARMAC review
6 March 2021 - The President of the Pacific Pharmacists’Association, Kasey Brown, says a review of New Zealand’s drug buying ...
Posted by Michael Wonder on 08 Mar 2021
Is the Department of Health guilty of abusing its monopsonistic power?
8 March 2021 - In these times of heightened sensitivities, is it time the folks in Canberra got called out ...
Posted by Michael Wonder on 08 Mar 2021
More startling revelations from the Public Summary Document for upadacitinib monohydrate (Rinvoq)
8 March 2021 - Take a seat before reading any further. ...
Posted by Michael Wonder on 08 Mar 2021
Jacinda Ardern responds to heartfelt plea from PHARMAC funding advocate Malcolm Mulholland
8 March 2021 - Prime Minister Jacinda Ardern has responded to a heartfelt plea by Malcolm Mulholland, a man advocating ...
Posted by Michael Wonder on 07 Mar 2021
PHARMAC does a great job, but it's losing the PR battle hands down
6 March 2021 - With each major change of government in recent years, PHARMAC has been required either to list ...
Posted by Michael Wonder on 01 Feb 2021
Determinants of managed entry agreements in the context of health technology assessment: a comparative analysis of oncology therapies in four countries
29 January 2021 - Managed entry agreements are increasingly used to address uncertainties arising in the health technology assessment process due ...
Posted by Michael Wonder on 31 Jan 2021
Evaluation of the impact of patient input in health technology assessments at NICE
29 January 2021 - Accounts of patient experiences are increasingly used in health technology assessment processes. However, we know little about ...
Posted by Michael Wonder on 24 Jan 2021
Creating a patient and community advisory committee at the Canadian Agency for Drugs and Technologies in Health
22 January 2021 - In recognition of patients’ roles using, and contributing to, a publicly funded health system, the Canadian Agency ...
Posted by Michael Wonder on 11 Jan 2021
Evaluating New Zealanders’ values for drug coverage decision-making: trade-offs between treatments for rare and common conditions
8 January 2021 - The objectives of this study were to measure the relative societal importance of values of New Zealanders ...
Posted by Michael Wonder on 22 Dec 2020
Shared decision making is an integral part of healthcare, says NICE
22 December 2020 - Shared decision making between patients and clinicians should be embedded throughout healthcare services, says NICE, in draft ...
Posted by Michael Wonder on 07 Dec 2020
Update on funding decision for two new diabetes medicines
7 December 2020 - PHARMAC would like to thank everyone who has provided feedback to date on a proposal to ...
Posted by Michael Wonder on 06 Dec 2020
Government promises independent PHARMAC review after Labour MPs veto Health Select Committee inquiry
3 December 2020 - National MPs have lashed out at Labour for voting against a politician-led inquiry into PHARMAC but ...
Posted by Michael Wonder on 04 Dec 2020
PHARMAC inquiry: “nothing should be off the table”
4 December 2020 - Medicines New Zealand, the industry association representing companies involved in the research, development and manufacture of ...